Comparative expression analysis of immune-related markers in surgically resected lung neuroendocrine neoplasms
(2023) In Lung Cancer 181.- Abstract
Background: Although immunotherapy has led to a paradigm shift in the treatment of lung cancer, the therapeutic approaches for lung neuroendocrine neoplasms (LNENs) are still limited. Our aim was to explore the immunological landscape and the expression of immune checkpoint markers in LNENs. Methods: Surgically removed tumor samples of 26 atypical carcinoid (AC), 30 large cell neuroendocrine carcinoma (LCNEC) and 29 small cell lung cancer (SCLC) patients were included. The immune phenotype of each tumor type was assessed by using a panel of 15 immune-related markers. As these markers are potentially expressed by immune cells and/or tumor cells, they might serve as putative targets for immunotherapy. Expression patterns were measured by... (More)
Background: Although immunotherapy has led to a paradigm shift in the treatment of lung cancer, the therapeutic approaches for lung neuroendocrine neoplasms (LNENs) are still limited. Our aim was to explore the immunological landscape and the expression of immune checkpoint markers in LNENs. Methods: Surgically removed tumor samples of 26 atypical carcinoid (AC), 30 large cell neuroendocrine carcinoma (LCNEC) and 29 small cell lung cancer (SCLC) patients were included. The immune phenotype of each tumor type was assessed by using a panel of 15 immune-related markers. As these markers are potentially expressed by immune cells and/or tumor cells, they might serve as putative targets for immunotherapy. Expression patterns were measured by immunohistochemistry and correlated with clinicopathological parameters and prognosis. Results: Unsupervised hierarchical clustering revealed distinct immunologic profiles across tumor types. Specifically, AC tumors were characterized by high tumor cell CD40 expression and low levels of immune infiltrates whereas SCLC samples had a high CD47 and Inducible T Cell Costimulator (ICOS) expression in tumor cells and immune cells, respectively. High CD70 and CD137 expression by tumor cells as well as elevated expression of CD27, Lymphocyte Activation Gene 3 (LAG3), and CD40 by immune cells were characteristic for LCNEC samples. Overall, SCLC and LCNEC tumors had a more immunogenic phenotype than AC samples. High tumor cell CD47 and CD40 expressions were associated with impaired and improved survival outcomes, respectively. Conclusions: By providing insights into the widely divergent immunologic profiles of LNENs, our results might serve as a basis for the development of novel immunotherapy-related approaches in these devastating malignancies.
(Less)
- author
- organization
- publishing date
- 2023-07
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Immune phenotype, Immune-related markers, Immunohistochemistry, Lung neuroendocrine tumors
- in
- Lung Cancer
- volume
- 181
- article number
- 107263
- publisher
- Elsevier
- external identifiers
-
- pmid:37270937
- scopus:85163260418
- ISSN
- 0169-5002
- DOI
- 10.1016/j.lungcan.2023.107263
- language
- English
- LU publication?
- yes
- id
- 57ec0a05-fb30-4e0f-a320-27c19bd68053
- date added to LUP
- 2023-09-15 10:18:27
- date last changed
- 2024-04-20 03:19:20
@article{57ec0a05-fb30-4e0f-a320-27c19bd68053,
abstract = {{<p>Background: Although immunotherapy has led to a paradigm shift in the treatment of lung cancer, the therapeutic approaches for lung neuroendocrine neoplasms (LNENs) are still limited. Our aim was to explore the immunological landscape and the expression of immune checkpoint markers in LNENs. Methods: Surgically removed tumor samples of 26 atypical carcinoid (AC), 30 large cell neuroendocrine carcinoma (LCNEC) and 29 small cell lung cancer (SCLC) patients were included. The immune phenotype of each tumor type was assessed by using a panel of 15 immune-related markers. As these markers are potentially expressed by immune cells and/or tumor cells, they might serve as putative targets for immunotherapy. Expression patterns were measured by immunohistochemistry and correlated with clinicopathological parameters and prognosis. Results: Unsupervised hierarchical clustering revealed distinct immunologic profiles across tumor types. Specifically, AC tumors were characterized by high tumor cell CD40 expression and low levels of immune infiltrates whereas SCLC samples had a high CD47 and Inducible T Cell Costimulator (ICOS) expression in tumor cells and immune cells, respectively. High CD70 and CD137 expression by tumor cells as well as elevated expression of CD27, Lymphocyte Activation Gene 3 (LAG3), and CD40 by immune cells were characteristic for LCNEC samples. Overall, SCLC and LCNEC tumors had a more immunogenic phenotype than AC samples. High tumor cell CD47 and CD40 expressions were associated with impaired and improved survival outcomes, respectively. Conclusions: By providing insights into the widely divergent immunologic profiles of LNENs, our results might serve as a basis for the development of novel immunotherapy-related approaches in these devastating malignancies.</p>}},
author = {{Ferencz, Bence and Megyesfalvi, Zsolt and Csende, Kristóf and Fillinger, János and Poór, Valentin and Lantos, András and Pipek, Orsolya and Sólyom-Tisza, Anna and Rényi-Vámos, Ferenc and Schelch, Karin and Lang, Christian and Schwendenwein, Anna and Boettiger, Kristiina and László, Viktória and Hoetzenecker, Konrad and Döme, Balázs and Berta, Judit}},
issn = {{0169-5002}},
keywords = {{Immune phenotype; Immune-related markers; Immunohistochemistry; Lung neuroendocrine tumors}},
language = {{eng}},
publisher = {{Elsevier}},
series = {{Lung Cancer}},
title = {{Comparative expression analysis of immune-related markers in surgically resected lung neuroendocrine neoplasms}},
url = {{http://dx.doi.org/10.1016/j.lungcan.2023.107263}},
doi = {{10.1016/j.lungcan.2023.107263}},
volume = {{181}},
year = {{2023}},
}